ARGX — H1 2026 Financial Report Analysis

VYVGART sales up 62% in H1 2026 and operating profit up 2.6x as spending grew much more slowly than sales

argenx sells one product family: VYVGART (an IV infusion) and VYVGART Hytrulo (an under-the-skin injection), both built on efgartigimod. The drug lowers the levels of the antibodies that the immune system turns against the body's own tissue. Its main markets are generalized myasthenia gravis (gMG), a chronic autoimmune disease in which those antibodies interrupt the signals between nerves and muscles and cause weakness, and CIDP, an autoimmune disorder that damages the insulation around nerves. In the six months to June 30, 2026, product net sales rose to $2,813 million from $1,739 million, up 62%. In the second quarter alone they reached $1,516 million, 60% more than a year earlier and 17% more than Q1 (about $1,297 million, which is the half-year total minus Q2). Costs rose much more slowly than sales, so the half-year operating profit rose from $340 million to $887 million and net profit roughly doubled to $838 million. argenx reports under IFRS in US dollars, and every figure here is in USD.

At a glance

• $1,516M Q2 product net sales (+60% YoY, +17% QoQ): growth is speeding up from one quarter to the next instead of levelling off. This is the first quarter that includes the US label expansion to every type of gMG patient, but the filing doesn't say how much of the growth came from it.
• 31.1% operating margin in H1 vs 19.2% a year ago: operating margin is the share of revenue left after running the business, before interest and tax. Research spending rose 45% and selling/admin costs rose 28%, both well below the 62% sales growth.
• $13.00 diluted EPS vs $6.32 (+106%): the half-year profit came in despite a $95 million swing from currency gains to currency losses. Excluding that swing, the underlying improvement was larger than the headline.

Results table (six months ended June 30)

"Revenue" here is the income statement's "total operating income": product net sales plus $41 million of "other operating income", which the company says "primarily relates to research and development tax incentives and payroll tax rebates." Gross margin, the share of sales left after the direct cost of making the drug, is calculated from product net sales minus cost of sales ($266 million vs $192 million). Net income is IFRS "profit for the period", all of it attributable to shareholders.

Where the sales came from

argenx reports a single business segment, but its interim report splits product net sales by the country where each sale is booked:

The US still provides about 85% of sales, so the 62% headline growth is mostly US growth. Japan roughly doubled, from a small base; there VYVGART is also approved for primary immune thrombocytopenia (ITP), an autoimmune disorder that destroys blood platelets. China is the only region that shrank, by half, though at $17 million it hardly moves the total. The filing gives no reason for the decline. The interim report also says sales are concentrated in a few customers: three US distributors and wholesalers accounted for about 72% of H1 product net sales.

The filing doesn't break sales down by indication (gMG vs CIDP) or by product (IV vs injection). The main commercial event this quarter was the US launch of an expanded label covering all gMG serotypes. Serotypes are patient subgroups defined by which antibody, if any, causes the disease. The label now includes "seronegative" patients, whose disease shows none of the usual antibodies. Because the launch happened during the quarter, Q2 shows only a small part of its effect.

Where the costs went

• Cost of sales rose 39% to $266 million, slower than sales, so gross margin improved to 90.5%. That level is typical of a high-priced biologic drug.
• R&D rose 45% to $929 million. The company says it "mainly relate[s] to advancing efgartigimod, empasiprubart, and adimanebart across multiple registrational studies, plus early-stage pipeline and preclinical programs." R&D fell from 36.2% to 32.6% of revenue. argenx is still increasing its research spending; the share fell only because sales grew faster. This line now also includes the loss from its joint-venture investment, and the prior-year figures were restated on the same basis.
• SG&A rose 28% to $772 million, driven by "professional and marketing fees linked to the global commercialization of the VYVGART franchise, and personnel expenses." It fell from 33.9% to 27.0% of revenue. Most of the margin gain came from this line: selling the drug to a larger patient base requires far less than a proportional increase in sales staff.

Q2 alone showed the same pattern: operating profit of $494 million vs $201 million, net profit of $472 million vs $245 million, and diluted EPS of $7.32 vs $3.74.

What the headline numbers hide

• Currency swung against the bottom line. The line "Exchange (losses)/gains" was a $19 million loss in H1 2026, compared with a $76 million gain in H1 2025. That $95 million reversal sits below operating profit. Before tax, profit nearly doubled ($958 million vs $489 million). Excluding FX in both years, pre-tax profit would have risen about 2.4x ($977 million vs $413 million), which shows the operating improvement more accurately than the headline net income growth does.
• A lower tax rate helped a little. Income tax expense was $119 million, an effective rate of about 12.4% compared with about 15.1% a year earlier. The rate stays low because of the tax incentives the company points to, including the Belgian "innovation income deduction" mentioned in its risk factors. A $110 million deferred tax benefit offset a $230 million current tax charge. That benefit doesn't bring in cash, and cash taxes actually paid jumped to $127 million from $10 million.
• Cash conversion is good but below 100%. Operating cash flow was $651 million, about 78% of net income. Trade receivables (money customers owe) rose from $1,490 million to $1,832 million in six months, which used $377 million of cash, and prepaid expenses used another $244 million. Some build-up in receivables is normal when sales grow 17% in a quarter, and the company reports no material credit-loss provision. One discrepancy: the press release says H1 2025 operating cash flow was "used" ($0.4 billion outflow), but the cash flow statement shows a $362 million inflow for H1 2025. We use the statement figure, so operating cash flow rose about 80% year on year.
• Inventory was drawn down. Inventories fell from $474 million to $371 million, mostly raw materials. Lower inventory frees up cash, but some of it may need to be rebuilt as volumes keep growing.
• Share count: a small boost to EPS. Diluted EPS (+106%) grew about 4 points faster than net income (+102%) because the weighted diluted share count fell from 65.7 million to 64.4 million. The basic share count actually rose (61.0 million to 62.2 million) as employees exercised options, which brought in $119 million in cash. The fall in the diluted count comes from how dilutive awards are counted, not from buybacks; argenx made no buybacks. Share-based compensation expense was $117 million.
• No numerical guidance. argenx gives no revenue or profit guidance, so there is no forecast to compare these results against. Its stated targets are operational ("Vision 2030": treat 50,000 patients, secure 10 labeled indications, and move five pipeline candidates into registrational studies by 2030).

Takeaway: argenx now earns a 31% operating margin on a single drug franchise while still increasing R&D by 45% a year. That is because SG&A grows at less than half the rate of sales. Its $5.2 billion in cash and its profits pay for the late-stage pipeline, so the company's value depends mainly on whether those trials succeed, not on raising money. The weak points are concentration: about 85% of sales come from the US and about 72% go through three US customers, so any pricing or reimbursement pressure in the US would hit the whole business.

What's next

The company says these registrational readouts are on track. "Registrational" means a late-stage study meant to support a regulatory approval:

• 3Q 2026 – ALKIVIA (VYVGART in myositis): myositis is a group of autoimmune diseases that inflame the muscles. This would be VYVGART's first indication in rheumatology. As of the July release, topline results were expected by the end of September. This report covers only the H1 filing and doesn't confirm whether those results have since come out.
• 4Q 2026 – EMPASSION (empasiprubart in multifocal motor neuropathy, MMN): empasiprubart is argenx's second drug, which blocks a different part of the immune system (complement C2). A positive result would give the company a second product beyond VYVGART.
• 1H 2027 – ADVANCE-NEXT (VYVGART in primary ITP); 2H 2027 – UNITY (Sjögren's disease) and the EMVIGORATE/EMNERGIZE CIDP studies of empasiprubart.
• 2027 – a VYVGART autoinjector launch for all approved indications; a planned expansion into ocular myasthenia gravis after positive ADAPT OCULUS results; and the next-generation FcRn molecule ARGX-213, designed for monthly dosing, which is now ready for Phase 3.

Next reports: Q3 2026 results on October 22, 2026, and full-year 2026 results on February 25, 2027.

Our read: The sales trend is strong. The 17% growth in Q2 over Q1 came before most of the effect of the seronegative label, and the fastest-growing cost line (R&D) is spending management chooses to make, not overhead that sales growth forces on it. Margins should keep improving as long as US growth continues. Three things to watch on October 22: whether Q3 sales grow again from Q2 (the first full quarter of the all-serotype label); whether receivables keep growing faster than sales; and the ALKIVIA result. A failed ALKIVIA trial wouldn't reduce current earnings, but it would remove one of the main ways for the company to grow beyond neurology.